Rnagene
This biopharmaceutical company develops mRNA-based therapies aimed at treating incurable diseases that current medical technologies cannot address. By focusing on innovative drug formulations, the company enhances patient outcomes and promotes long-term health.
- Biotechnology
Funding
Founders
Founder details are not available yet.
Product
Problem
Many diseases currently lack effective treatments, creating a significant unmet need for innovative therapeutic approaches. Traditional drug development methods often fail to address the underlying causes of these incurable conditions.
Solution
RNAGENE is a biopharmaceutical company focused on developing mRNA-based therapies for diseases with high unmet medical needs. The company leverages its platform technology to design and develop innovative mRNA medicines. These therapies aim to address the root causes of diseases that are currently difficult or impossible to treat with existing medical technologies. RNAGENE's approach involves multidisciplinary convergence and technological innovation to create new value in biopharmaceuticals.
Target Audience
The primary target audience includes patients suffering from incurable diseases and healthcare providers seeking innovative treatment options.
Features
- Development of prophylactic vaccines for SARS-CoV-2, Influenza, and Zika virus
- Immuno-oncology programs targeting NSCLC and multiple solid tumors
- Protein replacement therapy (PRT) for rare diseases
- Innovative mRNA design and formulation for enhanced therapeutic efficacy
- Pre-clinical and clinical-stage pipeline